PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer

Inclusion Criteria

• •1. Prior biopsy proven prostate cancer for which they underwent a radical prostatectomy with curative intent.
• •2. Evidence of biochemical recurrence as defined by NCCN: Persistent positive PSA post-radical prostatectomy (RP) or an undetectable PSA after RP with a subsequent detectable PSA that increases on ≥2 determinations (PSA recurrence) or increases to PSA \>0.1 ng/mL.
• •3. Targetable PSMA-avid lesion within the prostate bed, pelvic lymph nodes, or both and/or targetable lesion in prostate bed defined on MRI suspicious for local recurrence.
• •4. If lesions are amenable for biopsy this may be attempted, but biopsy proven recurrence/persistence is not required for trial enrollment.
• •5. Life expectancy greater than 5 years.
• •6. Karnofsky performance status ≥ 80 or Eastern Cooperative Oncology Group performance status ≤ 2 within 14 days prior to registration.
• •7. Age ≥ 30 years.
• •8. Patient must be able to provide study-specific informed consent prior to study entry.